News | September 27, 2024
USV launches Q rite tablets for treatment of rare aprhythmia in heart patients
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Quinidine Sulphate helps manage rare irregular heartbeat conditions
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Dyslipidemia is a critical risk factor for cardiovascular diseases
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Subscribe To Our Newsletter & Stay Updated
